TORONTO, April 03, 2023 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that it will participate in the Sequire Cannabis &

Source

Previous articleFILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Next articleReunion Neuroscience Appoints Dr. Fred Grossman to Board of Directors